Recursion Begin Period Cash Flow vs Depreciation Analysis
| RXRX Stock | USD 7.12 0.17 2.45% |
Recursion Pharmaceuticals financial indicator trend analysis is much more than just breaking down Recursion Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Recursion Pharmaceuticals is a good investment. Please check the relationship between Recursion Pharmaceuticals Begin Period Cash Flow and its Depreciation accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.
Begin Period Cash Flow vs Depreciation
Begin Period Cash Flow vs Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Recursion Pharmaceuticals Begin Period Cash Flow account and Depreciation. At this time, the significance of the direction appears to have totally related.
The correlation between Recursion Pharmaceuticals' Begin Period Cash Flow and Depreciation is 0.99. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Depreciation in the same time period over historical financial statements of Recursion Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Recursion Pharmaceuticals' Begin Period Cash Flow and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Recursion Pharmaceuticals are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Begin Period Cash Flow i.e., Recursion Pharmaceuticals' Begin Period Cash Flow and Depreciation go up and down completely randomly.
Correlation Coefficient | 0.99 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Recursion Pharmaceuticals value has been used up. For tax purposes Recursion Pharmaceuticals can deduct the cost of the tangible assets it purchases as business expenses. However, Recursion Pharmaceuticals must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Most indicators from Recursion Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Recursion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.At this time, Recursion Pharmaceuticals' Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.9 B in 2024, whereas Selling General Administrative is likely to drop slightly above 64.7 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 8.4M | 11.8M | 24.4M | 25.6M | Interest Income | 73K | 6.3M | 18.3M | 19.2M |
Recursion Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Recursion Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.